Myeloperoxidase (MPO) genotype and lung cancer histologic types: The MPO -463 a allele is associated with reduced risk for small cell lung cancer in smokers

International Journal of Cancer

Volumn 102, Issue 5, 2002, Pages 530-535

  Dally, Heike ^a   Gassner, Kai ^a   Jäger, Birgit ^a   Schmezer, Peter ^a   Spiegelhalder, Bertold ^a   Edler, Lutz ^a   Drings, Peter ^b   Dienemann, Hendrik ^b   Schulz, Volker ^b   Kayser, Klaus ^b   Bartsch, Helmut ^a   Risch, Angela ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer susceptibility; Lung cancer histologic type; Myeloperoxidase; Polymorphism; Small cell lung cancer

Indexed keywords

BENZO[A]PYRENE; CARCINOGEN; COAL TAR; MYELOPEROXIDASE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ADDUCT; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SMOKING; TOBACCO;

ADENOCARCINOMA; ADULT; ALLELES; CARCINOMA, SMALL CELL; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PEROXIDASE; RISK; SMOKING;

EID: 0037058697     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10756     Document Type: Article

References (36)

1. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol 2000;7:53-8.
2. Masuda M, Suzuki T, Friesen MD, Ravanat JL, Cadet J, Pignatelli B, Nishino H, Ohshima H. Chlorination of guanosine and other nucleosides by hypochlorous acid and myeloperoxidase of activated human neutrophils. Catalysis by nicotine and trimethylamine. J Biol Chem 2001;276:40486-96.
3. Petruska JM, Mosebrook DR, Jakab GJ, Trush MA. Myeloperoxidase-enhanced formation of (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene-DNA adducts in lung tissue in vitro: A role of pulmonary inflammation in the bioactivation of a procarcinogen. Carcinogenesis 1992;13:1075-81.
4. Austin GE, Lam L, Zaki SR, Chan WC, Hodge T, Hou J, Swan D, Zhang W, Racine M, Whitsett C. Sequence comparison of putative regulatory DNA of the 5′ flanking region of the myeloperoxidase gene in normal and leukemic bone marrow cells. Leukemia 1993;7:1445-50.
5. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271:14412-20.
6. Reynolds WF, Chang E, Douer D, Ball ED, Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997;90:2730-7.
7. Rojas M, Godschalk R, Alexandrov K, Cascorbi I, Kriek E, Ostertag J, van Schooten FJ, Bartsch H. Myeloperoxidase 463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients. Carcinogenesis 2001;22:1015-8.
8. Brockstedt U, Krajinovic M, Richer C, Mathonnet G, Sinnett D, Pfau W, Labuda D. Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs). Mutat Res 2002;516:41-7.
9. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res 1997;57:5001-3.
10. Schabath MB, Spitz MR, Hong WK, Delclos GL, Reynolds WF, Gunn GB, Whitehead LW, Wu X. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer 2002;37:35-40.
11. Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, Loddenkemper R, Roots I. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res 2000;60:644-9.
12. Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463G→a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:181-4.
13. Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis 2000;21:1163-6.
14. Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, Weinshenker BG. Myeloperoxidase -463 (G→A) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc 2002;77:17-22.
15. Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, Taylor PR, Albanes D. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett 2001;164:161-167.
16. Xu L, Miller DP, Liu G, Thurston SW, Fan R, Lynch TJ, Wain JC, Su L, Christiani DC. The Variant -G463A Polymorphism of the Myeloperoxidase (MPO) Gene Does Not Decrease Lung Cancer Susceptibility in a Caucasian Population. 2001;42:286.
17. Rosado-de-Christenson ML, Templeton PA, Moran CA. Bronchogenic carcinoma: Radiologic-pathologic correlation. Radiographics 1994;14:429-46.
18. Wikman H, Thiel S, Jager B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H, Risch A. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 2001;11:157-68.
19. Risch A, Wikman H, Thiel S, Schmezer P, Edler L, Drings P, Dienemann H, Kayser K, Schulz V, Spiegelhalder B, Bartsch H. Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics 2001;11:757-64.
20. Wikman H, Risch A, Klimek F, Schmezer P, Spiegelhalder B, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H. hOGG1 polymorphism and loss of heterozygosity (LOH): Significance for lung cancer susceptibility in a Caucasian population. Int J Cancer 2000;88:932-7.
21. Wittwer CT, Herrmann MG, Gundry CN, Elenitoba-Johnson KS. Real-time multiplex PCR assays. Methods 2001;25:430-42.
22. Breslow NE, Day NE. Statistical methods in cancer research. The Analysis of Case-Control Studies. Vol. 1. IARC Sci Publ. Lyon: IARC, 1980;32:5-338.
23. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G. Genetically based N-acetyltransferase metabolic polymorphism and lowlevel environmental exposure to carcinogens. Nature 1994;369:154-6.
24. Vineis P. Molecular epidemiology: Low-dose carcinogens and genetic susceptibility. Int J Cancer 1997;71:1-3.
25. Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A, Tajima K, Tominaga S. Low expression myeloperoxidase genotype negatively associated with Helicobacter pylori infection. Jpn J Cancer Res 2001;92:488-93.
26. Foster CB, Lehrnbecher T, Mol F, Steinberg SM, Venzon DJ, Walsh TJ, Noack D, Rae J, Winkelstein JA, Curnutte JT, Chanock SJ. Host defense molecule polymorphisms influence the risk for immunemediated complications in chronic granulomatous disease. J Clin Invest 1998;102:2146-55.
27. Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001;142:336-9.
28. Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002;40:2-8.
29. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999;149:13-20.
30. Brownson RC, Alavanja MC. Previous lung disease and lung cancer risk among women (United States). Cancer Causes Control 2000;11:853-8.
31. Osann KE, Lowery JT, Schell MJ. Small cell lung cancer in women: Risk associated with smoking, prior respiratory disease, and occupation. Lung Cancer 2000;28:1-10.
32. Brenner AV, Wang Z, Kleinerman RA, Wang L, Zhang S, Metayer C, Chen K, Lei S, Cui H, Lubin JH. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol 2001;30:118-24.
33. Pietra GG. The pathology of carcinoma of the lung. Semin Roentgenol 1990;25:25-33.
34. Clark RA, Szot S. The myeloperoxidase-hydrogen peroxide-halide system as effector of neutrophil-mediated tumor cell cytotoxicity. J Immunol 1981;126:1295-301.
35. Hoy A, Tregouet D, Leininger-Muller B, Poirier O, Maurice M, Sass C, Siest G, Tiret L, Visvikis S. Serum myeloperoxidase concentration in a healthy population: Biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 2001;9:780-6.
36. Garte S. Metabolic susceptibility genes as cancer risk factors: Time for a reassessment? Cancer Epidemiol Biomarkers Prev 2001;10:1233-7.